roslinct.comCrawled Nov 21, 2026
Lykan’s cell therapy analytical development team supports the transfer and establishment of analytical methods for partners.
The RoslinCT Training Academy is designed to train RoslinCT staff and other industry professionals looking to accelerate their careers in life sciences.
The webinar discusses the current state of induced pluripotent stem cell (iPSC) development and manufacturing, including potential applications of allogeneic manufacturing.
The latest cell therapy news, CDMO insights, and RoslinCT announcements
RoslinCT, a leading contract development and manufacturing organization (CDMO) for Advanced Cell and Gene therapies, announced the appointment of Derek Hei, Ph.D., to its Scientific Advisory Board (SAB).
London Climate Action Week is a collaborative event addressing the global climate emergency through clean economy acceleration, fair transitions, and private sector involvement.
Following a successful inspection at their Edinburgh, UK facility, from the Medicines and Healthcare products Regulatory Agency (MHRA), a Manufacturer’s Authorisation Licence (MIA) for commercial manufacturing of cell therapy products has been granted.
To decide between building a cell therapy facility or to outsource to a cell therapy CDMO requires weighing numerous factors - Lykan can help
RoslinCT, a leading CDMO focused on advanced cell therapies, announces investment from Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in global healthcare.
RoslinCT - a cell and gene therapy CDMO, developing life-changing cell and gene therapies – announces today the appointment of Peter Coleman as CEO.
RoslinCT - a cell and gene therapy CDMO, developing life-changing cell and gene therapies – announces the appointment of Alexandra Brownfield as Head of Business Development.
RoslinCT - a cell and gene therapy CDMO, developing life-changing cell and gene therapies – announces the appointment of Lee Warren as CFO.
RoslinCT - a cell and gene therapy CDMO, developing life-changing cell and gene therapies– signs lease for 1,453 sqm additional space at Charles Darwin House at the Edinburgh Technopole.
RoslinCT’s new cell and gene therapy manufacturing facility in Edinburgh was formally opened by Ian McCubbin CBE on behalf of Sir Patrick Vallance.
The latest career opportunities in the cell therapy industry, from supply chain, quality, engineering, manufacturing, and more
RoslinCT spoke with Derek Hei, Ph.D., Chief Technology Officer of Kenai Therapeutics, about advances in therapeutic uses of induced pluripotent stem cells (iPSCs).
Derek has over 30 years of experience developing cell and gene therapies with expertise in process/assay development, manufacturing and Quality Control testing in compliance with current Good Manufacturing Practices (cGMP), and regulatory affairs.
As a Co-Founder, General Manager, and facility architect, Matt was instrumental in making the company vision a reality.
Michael Mendicino, Ph.D. is a multi-disciplinary cell & gene therapy subject matter expert with over 24 years’ experience, educated in molecular/cellular biology/genetics, immunology, and regulatory science.
Patrick has nearly thirty years of experience in the biotechnology industry including corporate development, licensing, partnering, acquisition and financing through his various roles in executive leadership.
Sheli brings more than 20 years of diversified pharma and biotech experience which includes management of several global commercial teams, international distributors and other supporting functions necessary to grow sales revenue.
RoslinCT provides flexible, customized cell therapy solutions for partners.
RoslinCT develops advanced cell-based therapies with high quality.
Partner with an innovative, full-service cell therapy CDMO for cell therapy development and clinical & commercial manufacturing
Innovative cell & Gene therapy CDMO solutions for the US and EU markets for clinical and commercial cell therapy development and manufacturing